Last reviewed · How we verify
recombinant human thrombopoietin injection
At a glance
| Generic name | recombinant human thrombopoietin injection |
|---|---|
| Also known as | rhTPO |
| Sponsor | Shenyang Sunshine Pharmaceutical Co., LTD. |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- rhTPO Dose Escalation vs Eltrombopag Switch in ITP (NA)
- Romiplostim Versus rhTPO for Platelet Engraftment After Transplant in MDS and AA (PHASE2)
- Hetrombopag in Promoting Platelet Engraftment After Auto-HSCT in Children With Neuroblastoma (NA)
- Efficacy and Safety of rhTPO for the Treatment of Thrombocytopenia After Chemotherapy in AML Patients (PHASE4)
- Phase I Study to Evaluate rhTPO in Healthy Caucasian Volunteers (PHASE1)
- Evaluating the Efficacy and Safety of QL0911 in the Prevention of Chemotherapy- Induced Thrombocytopenia (PHASE2, PHASE3)
- Study of the Safety and Immunogenicity of Long-term GNR-069 Therapy in ITP Patients (PHASE3)
- A Multicenter Randomized Controlled Study on the Treatment of Refractory CTIT With Romiplostim N01 Compared to Recombinant Human Thrombopoietin (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |